Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , April 26, 2019 (GLOBE NEWSWIRE) -- Novo Nordisk today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in a tablet taken once-daily, for the treatment of
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , March 20, 2019 (GLOBE NEWSWIRE) -- Novo Nordisk announced today it has submitted two New Drug Applications (“NDA”) to the US Food and Drug Administration (“FDA”) for oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog utilizing Emisphere Technologies,
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a trials, both conducted with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1
View HTML
Toggle Summary Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide
MHR Converts $963,781 of Emisphere’s Debt to Equity and Emisphere Repays $1,000,000 of Existing Indebtedness held by MHR ROSELAND, N.J. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- On August 20, 2018 , Novo Nordisk A/S ( Novo Nordisk ) announced the headline results from PIONEER 5, a phase 3a trial with
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , June 29, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trial, PIONEER 3, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , June 21, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trials, PIONEER 4 and 7, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , May 31, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk (NYSE:NVO) announced Tuesday the completion of the second phase 3a trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary ELIGEN B12 Receives “Amazon’s Choice” Designation
ROSELAND, N.J. , May 30, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies , Inc. (OTCBB:EMIS) today announced that its non-prescription medical food product, Eligen B12, has earned the coveted “Amazon’s Choice” designation for being highly rated, fairly-priced, and available to ship immediately by
View HTML
Toggle Summary Emisphere Amends License Agreement with Novo Nordisk
Emisphere to Receive $7 Million Payment  ROSELAND, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB: EMIS ) today announced that it has amended its existing 2015 Development and License Agreement with Novo Nordisk A/S (NYSE: NVO ) for the development and
View HTML
Toggle Summary Emisphere Development Update
ROSELAND, N.J. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced today the successful completion of the first phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere
View HTML
Toggle Summary Emisphere Transitions to Non-Reporting Public Company
ROSELAND, N.J. , Aug. 11, 2017 (GLOBE NEWSWIRE) -- The Board of Directors of Emisphere Technologies , Inc. (OTCBB:EMIS) announced today that the Company intends to voluntarily terminate its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
View HTML
Toggle Summary Emisphere Reports First Quarter 2017 Financial Results
The Company to Host Conference Call Today at 8:30 AM ET
View HTML
Toggle Summary UPDATE -- Emisphere Announces First Quarter 2017 Earnings Conference Call
Conference Call/Webcast to be Held Friday, May 12, 2017, at 8:30 AM ET
View HTML
Toggle Summary Emisphere Announces First Quarter 2017 Earnings Conference Call
Conference Call/Webcast to be Held Friday, May 12, 2017, at 8:30 AM ET
View HTML
Toggle Summary Emisphere Reports Fourth Quarter and Full Year 2016 Financial Results
The Company to Host Conference Call Today at 8:30 AM ET
View HTML